Fact-checked by Grok 2 weeks ago

Rubefacient

A rubefacient is a topical pharmaceutical agent that induces redness and mild irritation of the skin through vasodilation and increased blood flow, serving primarily as a counterirritant to alleviate pain in musculoskeletal conditions. These substances work by creating a superficial inflammatory response that distracts from deeper tissue pain and may enhance local circulation. Common examples of rubefacients include salicylate-based compounds such as methyl salicylate, nicotinate esters such as methyl nicotinate, and natural irritants like capsaicin, menthol, and camphor. They are typically formulated as creams, gels, ointments, or liniments for external application to affected areas, such as muscles, joints, and tendons. Rubefacients have been employed for many years in the management of both acute and chronic pain, though systematic reviews indicate limited high-quality evidence supporting their efficacy beyond placebo in some cases. While generally considered safe for short-term use, rubefacients can cause side effects such as irritation, allergic reactions, or, in rare instances, systemic leading to , particularly with salicylate-containing products applied to large areas or broken . Their pharmacological action as counterirritants distinguishes them from other topical analgesics, like non-steroidal drugs, by focusing on sensory distraction rather than direct effects.

Definition and Etymology

Definition

A rubefacient is a substance applied topically to the skin that produces redness, known as erythema, by causing dilation of capillaries and an increased blood circulation to the affected area. Rubefacients are classified as a type of counterirritant, which distinguishes them from other topical agents such as anesthetics that numb sensory nerves or emollients that soften and hydrate the skin. These agents exhibit basic properties of being non-invasive and exerting primarily local effects on the skin, with minimal systemic absorption under typical use conditions.

Etymology

The term rubefacient originates from the Latin verb rubefacere, composed of ruber (or the variant stem rube-), meaning "red," and facere, meaning "to make," thus literally signifying "to make red." This etymological root reflects the primary observable effect of such substances on the skin, distinguishing them linguistically from other descriptors of topical agents. The word first appeared in English around the mid-17th century, with the earliest documented use in 1659 by English naturalist and physician Robert Lovell in his work on natural history and medicine. By the 18th and 19th centuries, rubefacient had become established in English pharmacological and medical texts to classify agents that produce localized redness, evolving alongside the formalization of dermatological terminology in Western medicine. In comparison to related irritant terms, rubefacient is unique in emphasizing (reddening) due to hyperemia, whereas vesicant denotes agents that raise blisters through more severe tissue damage, and pungent describes substances evoking a sharp, stinging sensory response without necessarily focusing on visible color change. These distinctions highlight rubefacient's specific association with mild, redness-inducing counterirritation in pharmacological .

Mechanism of Action

Physiological Mechanism

Rubefacients exert their effects primarily through local irritation of the skin, stimulating sensory nerve endings in the epidermis and dermis. This activation of nociceptors and thermoreceptors leads to depolarization of afferent nerve fibers and the release of inflammatory mediators, resulting in neurogenic inflammation and vasodilation. The irritation induces degranulation of cutaneous mast cells and release of vasoactive mediators such as histamine, which promote nitric oxide production and relaxation of arterioles. This culminates in increased capillary permeability and blood flow, manifesting as erythema (redness) typically observable within 1-5 minutes of application and peaking around 15-30 minutes. The enhanced circulation produces the characteristic rubor and a sensation of warmth, while also delivering oxygen and nutrients to superficial tissues. Mechanisms can vary by rubefacient type; for example, capsaicin acts via transient receptor potential vanilloid 1 (TRPV1) channels, while salicylates primarily cause direct irritation. At a central level, the counterirritation theory posits that the superficial sensory input generated by rubefacients competes with deeper nociceptive signals, thereby attenuating the perception of underlying . This distraction occurs via the gate control mechanism in the spinal cord's substantia gelatinosa, where non-noxious A-beta fiber inputs (evoked by the irritation) inhibit the transmission of noxious C-fiber signals through presynaptic inhibition and activation of descending modulatory pathways. By "closing the gate" to impulses, this physiological process reduces the relay of discomfort to higher brain centers, providing symptomatic relief without systemic effects.

Pharmacological Effects

Rubefacients, particularly salicylate-based formulations such as those containing methyl salicylate, exert local anti-inflammatory effects by penetrating the skin and inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis in underlying tissues. This mechanism contributes to decreased inflammation at the site of application, complementing their primary counterirritant action. Although the degree of systemic absorption and enzyme inhibition remains limited and variable depending on formulation and skin condition, studies indicate that topical salicylates can achieve therapeutic concentrations locally to modulate inflammatory mediators. The irritation induced by rubefacients enhances skin permeability, allowing for improved penetration of active ingredients into deeper subcutaneous and muscular layers. This effect is driven by localized vasodilation, which increases blood flow and facilitates drug distribution; for instance, methyl salicylate demonstrates self-promotion of its own deeper tissue penetration compared to non-irritant salicylate analogs. Such enhanced permeability is crucial for delivering anti-inflammatory and analgesic benefits to affected areas, though it is most pronounced in formulations applied to intact skin. The pharmacological effects of rubefacients are generally transient, with peak skin redness and vasodilation occurring shortly after application—typically within 5-10 minutes—and remaining elevated for 30-60 minutes before subsiding. Pain relief, mediated by both counterirritation and local anti-inflammatory actions, often persists longer, lasting 2-4 hours per application in acute musculoskeletal settings, necessitating repeated dosing for sustained therapy. These durations can vary based on concentration, vehicle, and individual factors like skin thickness.

Medical Uses

Indications

Rubefacients are primarily indicated for the management of acute musculoskeletal pain, including conditions such as sprains, strains, bruises, and sports injuries. These agents provide symptomatic relief by inducing localized skin irritation that distracts from underlying pain via counterirritation. In chronic settings, rubefacients are used for conditions like osteoarthritis, particularly for localized joint and soft tissue discomfort. They offer modest benefits in reducing pain and improving mobility in affected areas. As adjunctive therapies, rubefacients find application in sports medicine for minor injuries such as delayed-onset muscle soreness and tendonitis, aiding recovery and performance maintenance. In physiotherapy, they support soft tissue relief during rehabilitation for musculoskeletal disorders. Cochrane reviews indicate limited evidence for short-term relief in acute pain scenarios, with a number needed to treat (NNT) of approximately 3.2 for clinical success compared to placebo overall, though high-quality studies show no robust benefits and the evidence does not support their use. For chronic conditions, efficacy is limited, with an NNT of about 6.2 and inferior outcomes relative to topical NSAIDs.

Application Methods

Rubefacients are primarily administered topically to target localized areas of discomfort, utilizing various formulations designed for direct skin contact to facilitate absorption and irritation. Common forms include creams, gels, ointments, liniments, and patches, each offering distinct advantages in ease of application and duration of effect. Creams and gels provide a non-greasy base for quick absorption, while ointments offer a more occlusive layer for prolonged contact; liniments, typically liquid or semi-liquid, are rubbed in for immediate penetration; and patches deliver sustained release over several hours. Dosage and frequency vary by formulation but generally involve applying a thin layer or appropriate amount to the affected area 2 to 4 times daily, allowing sufficient time between applications for skin recovery. For creams, gels, ointments, and liniments, the product is gently massaged into the skin until absorbed, typically promoting vasodilation indicated by mild reddening as a sign of effective application. Patches are applied once or twice daily, adhering directly to the site without massage, and left in place for 8 to 12 hours before removal. Preparation for application emphasizes ensuring optimal skin conditions to maximize efficacy and minimize irritation. The target area must be clean and dry, with intact skin free from cuts or abrasions, prior to use; hands should be washed afterward to prevent accidental transfer. Application should strictly avoid the eyes, mucous membranes, and sensitive regions to prevent unintended exposure.

Examples of Rubefacients

Natural Rubefacients

Natural rubefacients are substances derived from plant sources that induce skin redness and warmth through local irritation, often employed in traditional medicine for their counterirritant effects. These agents typically activate sensory nerves and promote vasodilation, acting primarily locally with minimal systemic penetration. Capsaicin, the primary active compound in chili peppers (Capsicum species), belongs to the capsaicinoid family and serves as a potent rubefacient. Derived from the fruit's placental tissue, it binds to TRPV1 receptors on sensory neurons, triggering an initial intense burning sensation due to substance P release, which is followed by neuronal desensitization and reduced pain signaling upon repeated exposure. This property makes capsaicin useful in topical preparations for localized irritation and warmth. Menthol, extracted from mint plants such as Mentha piperita, acts as a rubefacient by providing a cooling sensation that paradoxically accompanies mild skin redness and increased blood flow. It activates ion channels, cold-sensitive receptors in sensory neurons, leading to a perceived cooling effect while stimulating mild in the cutaneous microvasculature. This dual action contributes to its use in ointments for superficial relief. Camphor, derived from the wood of the camphor tree (Cinnamomum camphora), is a natural terpenoid used as a rubefacient in topical analgesics. It induces a sensation of warmth and mild irritation by activating TRPV3 and TRPV1 channels, promoting local vasodilation and counterirritation to relieve musculoskeletal pain. Commonly found in balms and liniments, it enhances penetration of other active ingredients. Gingerol, a bioactive phenolic compound from the rhizome of ginger (Zingiber officinale), exhibits rubefacient qualities through its warming and circulatory-enhancing effects in traditional applications. Historically used in poultices—where grated fresh ginger is applied topically—it promotes local hyperemia and improved peripheral blood flow, aiding in the alleviation of musculoskeletal discomfort. These effects stem from gingerol's irritant properties on the skin and its ability to stimulate circulation with minimal systemic absorption.

Synthetic Rubefacients

Synthetic rubefacients are chemically synthesized compounds designed to induce redness and increased flow through , often optimized for consistent potency and in pharmaceutical applications. These agents are developed in laboratories to mimic or enhance the effects of natural irritants, allowing for precise dosing in topical formulations. Unlike plant-derived counterparts, synthetic versions enable large-scale production and standardization, reducing variability in efficacy. Methyl salicylate, also known as synthetic oil of wintergreen, is produced via esterification of salicylic acid with methanol, serving as a key synthetic analog of aspirin (acetylsalicylic acid) due to its shared salicylate structure. As a topical rubefacient, it penetrates the skin to cause counter-irritation, promoting local vasodilation and analgesia for musculoskeletal pain relief. It is widely incorporated into over-the-counter balms, liniments, and creams, where concentrations typically range from 10% to 30% to achieve therapeutic warming without excessive irritation. Nicotinates, such as methyl nicotinate, function primarily as peripheral vasodilators that elicit rubefacient effects by rapidly increasing cutaneous blood flow and inducing erythema upon topical application. This compound, a methyl ester of nicotinic acid, is applied in low concentrations (e.g., 0.5% to 1%) to provoke a measurable hyperemic response, making it valuable in diagnostic assessments of microvascular circulation and skin barrier integrity. In clinical settings, it is used in patch tests to evaluate vascular reactivity, such as in studies of endothelial function or inflammatory responses. Nonivamide, chemically pelargonic acid vanillylamide, is a fully synthetic analog of capsaicin engineered to replicate its vanillyl amide structure while offering improved chemical stability and reduced pungency variability. This allows for standardized potency in pharmaceutical formulations, where it is purified to 99% via high-performance liquid chromatography (HPLC) for consistent dosing in topical analgesics. As a rubefacient, nonivamide activates transient receptor potential vanilloid 1 (TRPV1) channels to produce localized irritation and heat sensation, enhancing penetration of co-administered actives in creams and patches for pain management.

Safety and Side Effects

Adverse Reactions

Rubefacients, by design, induce localized skin irritation to promote vasodilation and counterirritation, which can manifest as common adverse reactions including burning, stinging, or warmth at the application site. These sensations typically resolve within hours but may persist as excessive redness exceeding 24 hours in some users. Itching and mild rash are also frequently reported, with local skin reactions occurring in approximately 30-50% of individuals in clinical trials of topical capsaicin formulations, though often transient; rates are generally lower for menthol-based products. Severe local reactions are less common but can include blistering or allergic contact dermatitis, particularly with repeated exposure to sensitizing agents such as salicylates. Systemic effects from absorption are rare with standard topical use but may occur in high doses, leading to salicylate toxicity characterized by symptoms like tinnitus, nausea, or hyperventilation. Overall incidence of adverse events prompting withdrawal in studies is approximately 5-6%, higher than placebo rates of 1-2%.

Precautions and Contraindications

Rubefacients should not be applied to broken, infected, or damaged skin, as this can exacerbate irritation or lead to systemic absorption and potential toxicity. Hypersensitivity to active ingredients, such as salicylates or menthol, represents an absolute contraindication due to the risk of allergic contact dermatitis or anaphylactic reactions. For salicylate-containing formulations, their use is contraindicated in children under 2 years of age owing to the potential for salicylate toxicity akin to aspirin-related risks like Reye's syndrome; non-salicylate rubefacients like capsaicin should also be avoided in young children due to lack of established safety data. In pregnancy, salicylate-containing rubefacients classified as category C should be avoided unless benefits outweigh risks, given limited safety data and possible fetal effects from transdermal absorption; other rubefacients have minimal absorption but require caution. Precautions include performing a patch test on a small area of intact skin prior to full application to detect allergic responses. Users should discontinue application immediately if severe irritation, burning, or blistering occurs, and avoid covering treated areas with tight bandages to prevent enhanced absorption. Caution is advised when using salicylate-containing rubefacients concurrently with anticoagulants, as they may increase bleeding risk due to antiplatelet effects from potential systemic absorption. Additionally, avoid exposure to heat sources, exercise, or bathing for at least one hour after application to minimize burn risks or uneven absorption. Most rubefacients are available over-the-counter under FDA , but product labels must include warnings against use on compromised , in sensitive populations, and without consulting a healthcare provider for underlying conditions. Regulatory guidelines emphasize external use only, prohibiting application near eyes, mucous membranes, or open wounds to ensure safety.

History and Research

Historical Development

The historical development of rubefacients originated in ancient medical practices, where topical agents inducing skin redness were applied to alleviate pain through enhanced local circulation and counterirritation. Around 1500 BCE, ancient Egyptians employed rubefacients in herbal rubs and plasters to treat musculoskeletal disorders by stimulating blood flow, complemented by warming poultices for soothing relief. Specific remedies included celery and saffron applications for rheumatism, as documented in medical papyri like the Ebers Papyrus. The ancient Greeks further advanced these practices, with Hippocrates (c. 460–370 BCE) advocating turpentine as a rubefacient for pain management via skin application. Mustard plasters, used by Greek physicians including Hippocrates, were applied to address rheumatism, neuralgia, and other aches by drawing blood to the surface. In the 19th century, chemical synthesis transformed rubefacients from natural extracts to more potent formulations. Hermann Kolbe's 1860 isolation of salicylic acid via the Kolbe-Schmitt reaction from phenol marked a pivotal advancement, enabling the creation of synthetic salicylates like methyl salicylate for topical use. These compounds featured prominently in liniments, initially developed for veterinary applications such as horse treatments for strains and adapted for human musculoskeletal pain relief by the late 1800s. Early 20th-century standardization integrated rubefacients into formal pharmacopeias, including the British Pharmacopoeia of 1914, which outlined preparations like camphor liniments for consistent therapeutic application.

Modern Research

Modern research on rubefacients has primarily focused on evaluating their efficacy for pain management, particularly through systematic reviews and clinical trials targeting acute and chronic musculoskeletal conditions. A key Cochrane systematic review, originally published in 2009 and updated in 2014, analyzed 18 randomized controlled trials (RCTs) involving salicylate-containing rubefacients. For acute pain, the review found moderate evidence of benefit, with a relative risk (RR) of 1.9 and a number needed to treat (NNT) of 3.2 for at least 50% pain relief compared to placebo, based on four placebo-controlled studies with 324 participants; however, the evidence quality was rated very low due to methodological limitations in older, smaller trials. In contrast, for chronic pain, the evidence was inconclusive, with an RR of 1.6 and NNT of 6.2 across six placebo-controlled studies (455 participants), but larger recent studies showed no significant effect, leading to an overall conclusion that rubefacients do not robustly support efficacy for either acute or chronic musculoskeletal pain. Ongoing research has explored advanced formulations of capsaicin, a prominent natural rubefacient, to enhance targeted delivery for neuropathic pain while minimizing side effects. The U.S. Food and Drug Administration (FDA) approved Qutenza, an 8% capsaicin patch, in 2009 for postherpetic neuralgia, based on RCTs demonstrating significant pain reduction lasting up to 12 weeks with a single application. Subsequent trials and real-world studies from 2020 to 2025 have expanded its application to other neuropathic conditions, such as diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy, showing consistent pain relief (e.g., mean reductions of 30-50% in pain scores) and improvements in quality of life across diverse etiologies, with effects persisting for 3 months per treatment cycle. Additionally, investigations into nanoparticle-based delivery systems, such as lipid nanocarriers and poly(lactic-co-glycolic acid) nanoparticles loaded with capsaicin, have demonstrated enhanced transdermal penetration and reduced dermal irritation compared to conventional formulations, with in vitro and animal studies reporting up to 6-fold improved bioavailability and minimized burning sensations. Despite these advances, significant limitations persist in the evidence base for rubefacients as of 2025. Many trials suffer from small sample sizes (often under 100 participants per arm), increasing the risk of bias and limiting generalizability, as highlighted in the Cochrane update and echoed in recent observational studies on patches. Furthermore, there is a notable gap in high-quality RCTs examining long-term use beyond 3-12 months, with current data primarily short-term and focused on tolerability rather than sustained or profiles in broader populations.

References

  1. [1]
    Topical rubefacients for acute and chronic pain in adults - PMC
    Rubefacients (containing salicylates or nicotinamides) cause irritation of the skin, and are believed to relieve various musculoskeletal pains.
  2. [2]
    Salicylate‐containing rubefacients for acute and chronic ...
    Rubefacients are drugs that cause irritation and reddening of the skin due to increased blood flow. They are believed to relieve pain in various musculoskeletal ...
  3. [3]
    Making Sense of Topical Pain Relief Options - PubMed Central - NIH
    Oct 26, 2024 · Counterirritants, also called rubefacients, including capsaicin, menthol, camphor, and salicylate, work by causing irritation, vasodilation, and ...
  4. [4]
    Topical analgesics for acute and chronic pain in adults - PMC
    Topical rubefacients. Rubefacients cause irritation of the skin, and are believed to relieve pain in muscles, joints and tendons, and other musculoskeletal ...
  5. [5]
    (PDF) Salicylate Toxicity from Genital Exposure to a Methylsalicylate ...
    Methylsalicylate-containing rubefacients have been reported to cause salicylate poisoning after ingestion, topical application to abnormal skin, ...<|control11|><|separator|>
  6. [6]
    Irritants | Profiles RNS
    Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients.
  7. [7]
    Rubefacients - ISALTIS
    A rubefacient is a substance for topical application that produces redness of the skin e.g. by causing dilation of the capillaries and an increase in blood ...
  8. [8]
    Rubefacient - an overview | ScienceDirect Topics
    Rubefacients are substances that cause reddening of the skin and are often used topically to enhance sensation or relieve pain; they can be absorbed through ...
  9. [9]
    [PDF] Rubefacients and miscellaneous topical analgesics - PrescQIPP
    Rubefacients are topical preparations intended to relieve local pain in muscles, joints and tendons by counter-irritation. 1 The body of evidence for these ...
  10. [10]
    [PDF] Counterirritants and Sensory Profiling of Pain-Relieving Patches
    Nov 3, 2022 · Counterirritants are categorized into four groups based on their primary action: Group I agents include rubefacients like methyl salicylate; ...
  11. [11]
    Methyl salicylate: Uses, Interactions, Mechanism of Action - DrugBank
    Nov 30, 2015 · Approximately 12-20% of topically applied methyl salicylate may be systemically absorbed through intact skin within 10 hours of application, and ...<|control11|><|separator|>
  12. [12]
    Rubefacient - Etymology, Origin & Meaning
    Originating from Latin rubefacere, meaning "to make red," this word means causing redness or a substance that produces redness in the skin.
  13. [13]
    RUBEFACIENT Definition & Meaning - Merriam-Webster
    : causing redness (as of the skin) rubefacient 2 of 2 noun : a substance for external application that produces redness of the skin.
  14. [14]
    rubefacient, adj. & n. meanings, etymology and more
    OED's earliest evidence for rubefacient is from 1659, in the writing of Robert Lovell, naturalist. rubefacient is a borrowing from Latin. Etymons: Latin ...
  15. [15]
    RUBEFACIENT definition in American English - Collins Dictionary
    [1650–60; ‹ L rubefactus (ptp. of rubefacere; see rubefacient) + -ion]This word is first recorded in the period 1650–60. Other words that entered English at ...
  16. [16]
    Irritants MeSH Descriptor Data 2025 - MeSH Browser
    Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise ...
  17. [17]
  18. [18]
  19. [19]
    Histamine Is Released From Skin by Substance P but Does Not Act ...
    Histamine Is Released From Skin by Substance P but Does Not Act as the Final Vasodilator in the Axon Reflex. Br J Pharmacol. 1986 Aug;88(4):741-5.Missing: rubefacient mechanism counterirritation gate
  20. [20]
    OTC Transdermal Analgesic Patches in Pain Management
    Mar 15, 2019 · Counterirritants are medications that cause irritation and reddening of the skin that distract from more deep-seated pain.13,14. Topical ...
  21. [21]
    Counterirritant - an overview | ScienceDirect Topics
    The majority of rubefacient TAs fall into one of three categories: counterirritants, salicylates, and capsaicin. The physiological properties of each category ...Missing: classification | Show results with:classification
  22. [22]
    Self Promotion of Deep Tissue Penetration and Distribution of ...
    Purpose: To determine how changes in cutaneous blood flow induced in-vivo by methylsalicylate (MeSA), compared to non-rubefacient triethanolamine salicylate ...Missing: pharmacological | Show results with:pharmacological
  23. [23]
    Short-term cutaneous vasodilatory and thermosensory effects ... - NIH
    Apr 19, 2024 · Topical salicylates are considered to act primarily as rubefacients (Derry et al., 2014). Accordingly, several studies have recognized methyl ...
  24. [24]
    Introduction - Analgesics for Osteoarthritis - NCBI Bookshelf - NIH
    NSAIDs exert analgesic, anti-inflammatory, and antipyretic effects by blocking cyclooxygenases (COX), enzymes that are needed to produce prostaglandins.
  25. [25]
    Comprehensive review on additives of topical dosage forms for drug ...
    Liniments should not be applied to skin that is bruised or broken. Presence of the oil base or soap base providing ease of application and massage on affected ...Missing: avoid | Show results with:avoid
  26. [26]
    Liniment - an overview | ScienceDirect Topics
    Liniments are topical preparations used for their counterirritant effect, often applied to relieve discomfort associated with conditions like osteoarthritis.
  27. [27]
    Trolamine Salicylate Topical Dosage Guide + Max Dose, Adjustments
    Repeat as necessary, but no more than four times a day. Instructions for the Creme Rub: Apply generously to affected area. Massage into painful area until ...
  28. [28]
    Salonpas (Methyl Salicylate-Menthol) Topical: Uses, Side Effects ...
    Use this medication on the skin only. Clean and dry the affected area. Remove the backing from the patch and apply the patch to the affected area.Missing: rubefacient liniments method massage
  29. [29]
    Salonpas: Package Insert / Prescribing Information - Drugs.com
    Mar 24, 2025 · When using this product. wash hands after applying or removing patch. Avoid contact with eyes. If eye contact occurs, rinse thoroughly with ...Missing: liniments method massage
  30. [30]
    6.7 Administering Topical Medications – Clinical Procedures for ...
    Always clean the skin or wound before applying a new dose of topical medication. Checklist 53 lists the steps for applying a transdermal patch. Checklist 53: ...Missing: rubefacient massage
  31. [31]
    MenCaps Patch - DailyMed
    Capsaicin is an active component of chili peppers known clinically as a rubefacient. It acts as a counter-irritant by producing heat when in contact with human ...
  32. [32]
    Systematic review of topical capsaicin for the treatment of chronic pain
    Topical creams with capsaicin are used to treat pain from postherpetic neuralgia and diabetic neuropathy (0.075% cream 3-4 times daily for eight weeks), ...Missing: redness | Show results with:redness
  33. [33]
    Topical capsaicin (low concentration) for chronic neuropathic pain in ...
    Following application to the skin capsaicin causes enhanced sensitivity to noxious stimuli, followed by a period with reduced sensitivity and, after repeated ...
  34. [34]
    Biological Activities of Essential Oils: From Plant Chemoecology to ...
    In addition, the essential oils of some species of mint have often found external use for their astringent, rubefacient, antiseptic, and antimicrobial ...
  35. [35]
    TRPM8: The Cold and Menthol Receptor - TRP Ion Channel ... - NCBI
    Nonetheless, TRPM8 was the first cold-activated ion channel to be identified, and it established the general role for TRP ion channels in thermosensation [1].THE CLONING OF A COLD... · TRPM8 HAS PROPERTIES... · OTHER COOLING...
  36. [36]
    Topical menthol increases cutaneous blood flow - PMC - NIH
    Apr 27, 2016 · Topically applied menthol, but not ilex, dose-dependently increases blood flow in the cutaneous microvasculature.Missing: mint rubefacient
  37. [37]
    Herbal antioxidant in clinical practice: A review - PMC
    Externally, ginger is a rubefacient, and has been believed to relief headache and toothache.
  38. [38]
    Topical Ginger Treatment With a Compress or Patch for ... - PMC
    Topical ginger treatment has the potential to relieve symptoms, improve the overall health, and increase independence of people with chronic osteoarthritis.
  39. [39]
    Methyl Salicylate | C8H8O3 | CID 4133 - PubChem
    Methyl salicylate relieve musculoskeletal pain in the muscles, joints, and tendons by causing irritation and reddening of the skin due to dilated capillaries ...<|control11|><|separator|>
  40. [40]
    Methyl salicylate | 119-36-8 - ChemicalBook
    It is produced by esterificationof salicylic acid with methanol. It is used inperfumery and as a flavoring agent. Uses. In high concentrations as a rubefacient ...
  41. [41]
    Methyl nicotinate: Uses, Interactions, Mechanism of Action - DrugBank
    Sep 6, 2017 · Following topical administration, methyl nicotinate acts as a peripheral vasodilator to enhance local blood flow at the site of application. It ...
  42. [42]
    methyl nicotinate in aqueous solution at various temperatures
    The rubefacient activity of methyl nicotinate is assumed to involve peripheral vasodilation. Methyl nicotinate is used in veterinary medicine to treat ...
  43. [43]
    Reflectance spectroscopy: a non-invasive strategy to explore skin ...
    Jun 18, 2024 · Methyl nicotinate is a rubefacient substance that induces local erythema and redness, due to a transient increase in the skin perfusion (Elawa ...
  44. [44]
    Nonivamide - an overview | ScienceDirect Topics
    Nonivamide, or PAVA, is a synthetic form of capsaicin, originally found in peppers, but mostly derived from synthesis.
  45. [45]
    Nonivamide Specification - Rebecca
    The pinnacle of Nonivamide powder purity is the 99% specification, typically verified through high-performance liquid chromatography (HPLC). This highest-grade ...
  46. [46]
    Nonivamide Powder: A Complete Guide for Industrial Applications
    Sep 25, 2025 · Nonivamide is widely used in pharmaceutical formulations for its warming and pain-relieving properties: Pain relief creams & ointments: Used in ...
  47. [47]
    Topical NSAIDs for acute musculoskeletal pain in adults - PMC
    They reversibly inhibit cyclooxygenase (prostaglandin endoperoxide synthase), the enzyme mediating production of prostaglandins and thromboxane A2 (FitzGerald ...
  48. [48]
    Capsaicin (topical route) - Side effects & dosage - Mayo Clinic
    Apr 30, 2025 · You may have some skin redness, burning, or a stinging sensation at the application site. Heat, humidity, bathing in warm water, or sweating ...Missing: rubefacient | Show results with:rubefacient
  49. [49]
    Topical capsaicin for pain in osteoarthritis: A literature review
    Redness and local burning sensation were the most frequently reported side effects in the capsaicin group (44–46% of patients in two studies). The main ...
  50. [50]
    Salicylic Acid Methyl Ester - an overview | ScienceDirect Topics
    Methyl Salicylate​​ The most common adverse effects are skin irritation and rash, but more severe skin reactions along with systemic toxicity can occur.
  51. [51]
    Unmasking the Hidden Risk of Systemic Toxicity from Topical ... - NIH
    Sep 1, 2025 · Despite their widespread use, topical salicylates can be absorbed enough to cause systemic toxicity particularly when a large dose of high ...
  52. [52]
    Potential dangers from topical preparations containing methyl ...
    Methyl salicylate in topical analgesic preparations may cause irritant or allergic contact dermatitis and anaphylactic reactions.Missing: precautions | Show results with:precautions
  53. [53]
    Methyl Salicylate-Menthol Topical: Uses, Side Effects, Interactions ...
    Precautions. Before using this product, tell your doctor or pharmacist if you are allergic to menthol or methyl salicylate; or to aspirin or other salicylates ...
  54. [54]
    methyl salicylate-menthol topical ointment - Kaiser Permanente
    Do not apply this medication to skin that is injured or irritated (such as cut, scraped, sunburned). Do not bandage or tightly wrap the affected area. Doing so ...
  55. [55]
    Rare cases of serious burns with the use of over-the-counter topical ...
    Sep 13, 2012 · Do not apply OTC topical muscle and joint pain relievers to wounds or damaged, broken, or irritated skin. Also do not allow contact with eyes ...Missing: precautions | Show results with:precautions
  56. [56]
    Counterirritants
    Oct 28, 2025 · For external use only. · Avoid contact with the eyes and mucous membranes (US FDA 1983). · Do not apply to wounds or damaged skin (US FDA 1983).Missing: precautions | Show results with:precautions
  57. [57]
    Egyptians, not Greeks, were true fathers of medicine
    May 9, 2007 · Further evidence showed that musculo-skeletal disorders were treated with rubefacients to stimulate blood flow and poultices to warm and soothe.
  58. [58]
    COMPARISON OF RUBEFACIENT OINTMENTS BY SKIN ...
    MEDICAL history contains many references to the treatment of pain by application of rubefacients to the skin. Turpentine was advocated by. Hippocrates ...
  59. [59]
    Does Mustard Plaster Work for Coughs and Colds? - Healthline
    Sep 30, 2020 · The Greek physician Hippocrates allegedly used mustard packs to treat lung problems in ancient Greece. According to users and proponents of ...Does it work? · How to make one · Safety · Alternative treatments
  60. [60]
    Kolbe-Schmitt Synthesis - an overview | ScienceDirect Topics
    The Kolbe–Schmitt reaction was developed in 1860 by Kolbe, and the yield was improved under reaction conditions at 125 °C and 4–7 atm carbon dioxide pressure ...Missing: rubefacients | Show results with:rubefacients
  61. [61]
    Topical Analgesics - Wood Library-Museum of Anesthesiology (WLM)
    In the 19th Century, many topical agents were patent medicines that made ... This ointment contained methyl salicylate, which is a counterirritant.
  62. [62]
    [PDF] British Pharmacopoeia
    Arsenic limit 5 parts per million. Hydrochloric acid to which sodium sulphite has been added, when poured carefully upon an equal volume of Sulphuric Acid ...
  63. [63]
  64. [64]
    Drug Approval Package: Qutenza (capsaicin) NDA #022395
    Jun 29, 2010 · Drug Approval Package Qutenza (capsaicin) 8% patch. Company: Neurogesx, Inc. Application No.: 022395. Approval Date: 11/16/2009.
  65. [65]
    Nanomaterial Lipid-Based Carrier for Non-Invasive Capsaicin Delivery
    Nov 27, 2020 · The chili-extract-loaded NLCs were shown to be applicable for the transdermal delivery of capsaicin whilst minimizing skin irritation, the major ...Missing: rubefacient | Show results with:rubefacient
  66. [66]